Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Theravance Biopharma (TBPH) Cash from Operations: 2012-2024

Historic Cash from Operations for Theravance Biopharma (TBPH) over the last 13 years, with Dec 2024 value amounting to -$11.5 million.

  • Theravance Biopharma's Cash from Operations fell 25.25% to -$6.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $243.7 million, marking a year-over-year increase of 2221.55%. This contributed to the annual value of -$11.5 million for FY2024, which is 57.27% up from last year.
  • Latest data reveals that Theravance Biopharma reported Cash from Operations of -$11.5 million as of FY2024, which was up 57.27% from -$27.0 million recorded in FY2023.
  • Theravance Biopharma's 5-year Cash from Operations high stood at -$11.5 million for FY2024, and its period low was -$262.7 million during FY2020.
  • Over the past 3 years, Theravance Biopharma's median Cash from Operations value was -$27.0 million (recorded in 2023), while the average stood at -$75.2 million.
  • In the last 5 years, Theravance Biopharma's Cash from Operations declined by 10.31% in 2020 and then surged by 85.56% in 2023.
  • Over the past 5 years, Theravance Biopharma's Cash from Operations (Yearly) stood at -$262.7 million in 2020, then increased by 10.27% to -$235.8 million in 2021, then rose by 20.69% to -$187.0 million in 2022, then soared by 85.56% to -$27.0 million in 2023, then spiked by 57.27% to -$11.5 million in 2024.